FINADYNE® Transdermal Pour-on Solution Now Available for Mastitis
Merck Animal Health to Feature Product at European Buiatrics Congress in Rome
MADISON, NEW JERSEY, October 15, 2015 – Merck Animal Health (known as MSD Animal Health outside the United States and Canada) today announced FINADYNE® Transdermal (flunixin meglumine) pour-on solution can now be used to reduce pyrexia associated with acute mastitis. This claim adds to the already proven efficacy to reduce pyrexia associated with Bovine Respiratory Disease.
“This additional claim for FINADYNE Transdermal pour-on allows for a more convenient way to relieve animals from fever, improve respiratory and depression scores associated with Bovine Respiratory Disease (BRD) and mastitis,” said Siddartha Torres, Technical Director, Merck Animal Health. “FINADYNE Transdermal is making its mark as the world’s first non-parasiticide cattle product available with a transdermal route of administration and builds on the legacy of FINADYNE as the pioneer injectable non-steroidal anti-inflammatory drug.”
The company will showcase FINADYNE Transdermal pour-on at the European Buiatrics Congress in Rome, Italy October 14-16 with special emphasis during a 90 minute symposium on Thursday October 15. During the session, attendees will learn more about the science behind the claim and the practical benefits of using it to control inflammation. Additionally, FINADYNE Transdermal will be featured in a series of interviews and discussions on the extremely informative Studio Bovine during and after the Congress.
FINADYNE Transdermal goes to work quickly and has been demonstrated to reduce fever as early as four hours after administration. Studies show the reduction of inflammation in the udder is also rapid, alleviating the swelling pain associated with acute mastitis, a significant factor in cow comfort. The innovative technology of FINADYNE Transdermal allows for rapid absorption of flunixin through the skin and into the bloodstream. The efficient administration means there is no need for additional labor, head gates or restraint commonly associated with injectable administration, which translates to reduced cost per treatment.
This new approach to reducing fever in cattle is in alignment with industry efforts to continuously improve animal care. The pour-on application requires less handling, resulting in less stress on animals and leading to inherent health and wellness advantages. It also offers the added benefit of needle-free administration, with no injection site lesions and a higher-value end product.
To learn more about FINADYNE® Transdermal Pour-on, visit www.merck-animal-health.com.
About Merck Animal Health
Today’s Merck is a global healthcare leader working to help the world be well. Merck Animal Health, known as MSD Animal Health outside the United States and Canada, is the global animal health business unit of Merck. Through its commitment to the Science of Healthier Animals™, Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com or connect with us on LinkedIn and Twitter.
Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2014 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).